Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall M Stevens

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|April 18, 2020
ReplyRandall M Stevens, James N Campbell, Peter D Hanson
The Journal of Rheumatology|April 17, 2013
Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled studyVibeke Strand, Georg Schett, Chiachi Hu, et al.
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseasesGeorg Schett, Victor S Sloan, Randall M Stevens, et al.
Health and Quality of Life Outcomes|May 14, 2013
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled studyVibeke Strand, David Fiorentino, ChiaChi Hu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 20, 2019
Randomized, Double-Blind, Placebo-Controlled Trial of Intraarticular Trans-Capsaicin for Pain Associated With Osteoarthritis of the KneeRandall M Stevens, John Ervin, Jennifer Nezzer, et al.
The New England Journal of Medicine|June 18, 2004
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritisJonathan C W Edwards, Leszek Szczepanski, Jacek Szechinski, et al.
Annals of the Rheumatic Diseases|January 22, 2016
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Christopher J Edwards, Francisco J Blanco, Jeffrey Crowley, et al.
The Journal of Rheumatology|April 3, 2003
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritisRolf Rau, Oliver Sander, Piet van Riel, et al.
The Journal of Rheumatology|October 7, 2003
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritisDaniel E Furst, Michael Weisman, Harold E Paulus, et al.
The Journal of Rheumatology|September 17, 2015
Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014Gulen Hatemi, Yesim Ozguler, Haner Direskeneli, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Arthritis & Rheumatology (Hoboken, N.J.)|April 18, 2020
ReplyRandall M Stevens, James N Campbell, Peter D Hanson
The Journal of Rheumatology|April 17, 2013
Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled studyVibeke Strand, Georg Schett, Chiachi Hu, et al.
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseasesGeorg Schett, Victor S Sloan, Randall M Stevens, et al.
Health and Quality of Life Outcomes|May 14, 2013
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled studyVibeke Strand, David Fiorentino, ChiaChi Hu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 20, 2019
Randomized, Double-Blind, Placebo-Controlled Trial of Intraarticular Trans-Capsaicin for Pain Associated With Osteoarthritis of the KneeRandall M Stevens, John Ervin, Jennifer Nezzer, et al.
The New England Journal of Medicine|June 18, 2004
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritisJonathan C W Edwards, Leszek Szczepanski, Jacek Szechinski, et al.
Annals of the Rheumatic Diseases|January 22, 2016
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Christopher J Edwards, Francisco J Blanco, Jeffrey Crowley, et al.
The Journal of Rheumatology|April 3, 2003
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritisRolf Rau, Oliver Sander, Piet van Riel, et al.
The Journal of Rheumatology|October 7, 2003
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritisDaniel E Furst, Michael Weisman, Harold E Paulus, et al.
The Journal of Rheumatology|September 17, 2015
Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014Gulen Hatemi, Yesim Ozguler, Haner Direskeneli, et al.
Pageof 2